Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation
NCT04872621 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 104
Last updated 2025-09-02
Summary
To understand the incidence of ADRs of Calquence 100 mg capsules (acalabrutinib) used in patients with relapsed or refractory chronic lymphocytic leukaemia (including small lymphocytic lymphoma) in a real-world post-marketing setting
Conditions
- Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Toshimitsu Tokimoto · AstraZeneca KK
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-06-30
- Primary Completion
- 2024-09-04
- Completion
- 2024-09-04
Countries
- Japan
Study Locations
More Related Trials
-
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
NCT01908387 ·Status: TERMINATED ·Phase: PHASE1
-
Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
NCT04930536 ·Status: COMPLETED ·Phase: PHASE4
-
AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database
NCT06548152 ·Status: RECRUITING
-
Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
NCT04402138 ·Status: COMPLETED ·Phase: PHASE2
-
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
NCT06651970 ·Status: RECRUITING ·Phase: PHASE4
-
CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey
NCT03647215 ·Status: COMPLETED
-
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
NCT04716075 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
NCT02717611 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
NCT03932331 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies
NCT03198650 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
NCT02477696 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT03516617 ·Status: RECRUITING ·Phase: PHASE2
-
Lenalidomide in Patients With Chronic Myelomonocytic Leukemia
NCT01368757 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia
NCT00109356 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)
NCT04198415 ·Status: COMPLETED
-
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia
NCT01649791 ·Status: TERMINATED ·Phase: NA
-
A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia
NCT01808326 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
NCT04075292 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
NCT04215809 ·Status: RECRUITING ·Phase: PHASE1
-
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia
NCT00742144 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00496132 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
NCT00462761 ·Status: COMPLETED ·Phase: PHASE1
-
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
NCT02213926 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans
NCT04126707 ·Status: COMPLETED ·Phase: PHASE1